Viking Therapeutics: Great Clinical Results Do Not Guarantee Commercialization Success

wragg For this particular article, we will be looking at Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) and sharing our findings about the stock, continuing the theme surrounding obesity therapies. VKTX For now, VK2735 has already reported excellent results from its phase 2 clinical trials, with 14.7% of weight loss from base line by Week 13 (subcutaneous injection) and 5.3% by Day 28 (oral). These numbers are very promising indeed, since it delivers excellent weight losses compared to NVO's Wegovy at -7% a ...